LIPOSOMES FOR PULMONARY APPLICATIONS

Authors
  1. Shek, P.N.
  2. Barber, R.F.
  3. Jurima-Romet, M.
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN)
Abstract
The potential applications of liposomes for drug delivery to the lung appear promising. There are apparent advantages associated with liposome-mediated targeting of entrapped agents to the respiratory system as already described in this review. The successful delivery of liposome-encapsulated drugs to the lung, either directly via the nasopharyngeal route or indirectly by parenteral administrations, usually produces prolonged drug retention in the lung, reduced systemic toxicity, and decreased extrapulmonary side-effects. The last two advantages are clearly important in rendering certain highly toxic drugs clinically useful for the treatment of specific lung conditions. Indeed, encapsulation and delivery in liposomes may substantially increase the therapeutic efficacy of a drug.
Report Number
DCIEM-90-P-21 — Research Paper; Reprint Contains Parts 1 and 2 of the report
Date of publication
15 Feb 1990
Number of Pages
14
Reprinted from
Modern Medicine of Canada, vol 45, no 2-3, 1990, p 135-141, 233-237
DSTKIM No
90-03537
CANDIS No
65786
Format(s):
Hardcopy;Originator's fiche received by DSIS

Permanent link

Document 1 of 1

Date modified: